SCHEMBL3497134

SCHEMBL3497134

Cc1ccccc1N1C(=O)C2C3CCC(O3)C2C1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 1.00
KMT2A Q03164 3/20 0.51
MAPT P10636 2/20 0.51
MEN1 O00255 2/20 0.51
MGLL Q99685 1/20 0.47
ALDH1A1 P00352 4/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
GAA P10253 1/20 0.42
ELANE P08246 1/20 0.41
CASP3 P42574 1/20 0.41
CASP6 P55212 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
TSHR P16473 1/20 0.40
DDB1 Q16531 1/20 0.40
CRBN Q96SW2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3496324 0.81 L3MBTL1 (0.68) L3MBTL1KMT2AMAPTMEN1MGLL
SCHEMBL3495027 0.80 L3MBTL1 (0.67) L3MBTL1KMT2AMAPTMEN1MGLL
SCHEMBL3496114 0.79 L3MBTL1 (0.65) L3MBTL1KMT2AMAPTMEN1GAA
SCHEMBL3182076 0.79 L3MBTL1 (0.65) L3MBTL1SMN1; SMN2TDP1TSHR
SCHEMBL3182085 0.79 L3MBTL1 (0.65) L3MBTL1SMN1; SMN2TDP1TSHR
SCHEMBL15836588 0.76 MEN1 (0.65) L3MBTL1KMT2AMEN1ALDH1A1GAA
SCHEMBL10038047 0.76 MEN1 (0.65) L3MBTL1KMT2AMEN1ALDH1A1GAA
SCHEMBL3495788 0.76 MEN1 (0.65) L3MBTL1KMT2AMEN1ALDH1A1GAA
SCHEMBL27735471 0.76 L3MBTL1 (0.60) L3MBTL1KMT2AMAPTMEN1MGLL
SCHEMBL5515994 0.75 MEN1 (0.66) L3MBTL1KMT2AMAPTMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137294-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS GENETIC TECHNOLOGIES LIMITED (AU) 2010-06-03 US claimed
EP-2086534-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS Genetic Technologies Limited (AU) 2009-08-12 EP claimed
WO-2008058342-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS GENETIC TECHNOLOGIES LIMITED (AU) 2008-05-22 WO claimed
US-20100137294-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS GENETIC TECHNOLOGIES LIMITED (AU) 2010-06-03 US disclosed
EP-2086534-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS Genetic Technologies Limited (AU) 2009-08-12 EP disclosed
WO-2008058342-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS GENETIC TECHNOLOGIES LIMITED (AU) 2008-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137294-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS PPP1R10, TASP1, PPP5C L3MBTL1 598/4885KMT2A 1199/4885MAPT 1965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.